The viral structural spike (S) protein binds to the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry to cells; this has led to suggestions that use of ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) may be implicated in poorer outcomes with COVID-19 [17, 18]. Here, ACE is linked to COVID-19.